{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T11:24:13Z","timestamp":1770549853113,"version":"3.49.0"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T00:00:00Z","timestamp":1769644800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,2,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To compare the severity at diagnosis and disease activity during follow-up between juvenile (jDM) and adult-onset (aDM) dermatomyositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with DM fulfilling the 2017 ACR\/EULAR criteria and tested for myositis-specific antibodies were included. Overall severity at diagnosis was defined by at least one of the following: severe muscle impairment, symptomatic interstitial lung disease (ILD), gastrointestinal (GI) vasculitis, myocarditis, severe skin ulceration or admission to an intensive care unit. Clinically inactive disease and remission were defined according to PRINTO group criteria and IMACS guidelines.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Two hundred and one patients were included: 123 with aDM (\u226518\u2009years) and 78 with jDM (&amp;lt;18\u2009years). Female predominance was less pronounced and GI involvement was more frequent in jDM. Anti-nuclear matrix protein 2 (NXP2) antibodies (Abs) were more frequent in jDM. Severe disease at diagnosis was present in 44% of cases, with symptomatic ILD more common in adults and GI vasculitis more common in children. No difference was observed in severe muscle disease. In jDM, anti-NXP2 Abs (odds ratio [OR]\u2009=\u20096.29 [2.00, 23.07], P\u2009=\u20090.003) and joint involvement (OR\u2009=\u20093.44 [1.33, 11.47], P\u2009=\u20090.03) were associated with severe disease at diagnosis, while in aDM, anti-Mi2 Abs were associated with a lower likelihood of severe disease (OR\u2009=\u20090.12 [0.02, 0.42], P\u2009=\u20090.003). No significant difference was observed in clinically inactive disease or remission at the last follow-up. Severe infections occurred in 25% of patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Severity profiles differ by age of DM onset. Autoantibodies are key indicators of severity at diagnosis in both juvenile DM and adult DM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/rheumatology\/keag032","type":"journal-article","created":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T12:45:19Z","timestamp":1768999519000},"source":"Crossref","is-referenced-by-count":0,"title":["Comparison of disease severity and activity between juvenile- and adult-onset dermatomyositis: a multicentre cohort study"],"prefix":"10.1093","volume":"65","author":[{"given":"Agathe","family":"Sinnaeve","sequence":"first","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et immunologie clinique, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigitte","family":"Bader-Meunier","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019Immunologie, d\u2019h\u00e9matologie et rhumatologie p\u00e9diatrique, h\u00f4pital Necker, APHP , Paris,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Mirguet","sequence":"additional","affiliation":[{"name":"D\u00e9partement de n\u00e9phrologie p\u00e9diatrique, H\u00f4pital d\u2019enfants, CHRU Nancy , Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4134-6086","authenticated-orcid":false,"given":"Thomas","family":"Moulinet","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et immunologie clinique, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]},{"name":"UMR 7365 CNRS-Universit\u00e9 de Lorraine IMoPA, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ir\u00e8ne","family":"Lemelle","sequence":"additional","affiliation":[{"name":"D\u00e9partement d\u2019onco-h\u00e9matologie p\u00e9diatrique, H\u00f4pital d\u2019enfants, CHRU Nancy , Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3281-7299","authenticated-orcid":false,"given":"Anne-Claire","family":"Bursztejn","sequence":"additional","affiliation":[{"name":"Service de dermatologie, CHRU Nancy , Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jo\u00eblle","family":"Terzic","sequence":"additional","affiliation":[{"name":"D\u00e9partement de P\u00e9diatrie, H\u00f4pitaux universitaires de Strasbourg , Strasbourg,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariane","family":"Zaloszyc","sequence":"additional","affiliation":[{"name":"D\u00e9partement de P\u00e9diatrie, H\u00f4pitaux universitaires de Strasbourg , Strasbourg,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alain","family":"Meyer","sequence":"additional","affiliation":[{"name":"D\u00e9partement de rhumatologie, H\u00f4pitaux universitaires de Strasbourg , Strasbourg,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thierry","family":"Martin","sequence":"additional","affiliation":[{"name":"Service d\u2019immunologie clinique, Centre de r\u00e9f\u00e9rence des maladies auto-immunes rares RESO, H\u00f4pitaux universitaires de Strasbourg , Strasbourg,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claire","family":"Ballot-Schmit","sequence":"additional","affiliation":[{"name":"D\u00e9partement de P\u00e9diatrie, CHU Besan\u00e7on , Besan\u00e7on,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Campagne","sequence":"additional","affiliation":[{"name":"Service de m\u00e9decine interne, UNEOS , Metz,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lo\u00efs","family":"Bolko","sequence":"additional","affiliation":[{"name":"D\u00e9partement de rhumatologie, CHU Reims , Reims,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Bonnotte","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne, CHU Dijon , Dijon,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roland","family":"Jaussaud","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et immunologie clinique, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]},{"name":"EA 3450 DevAH\u2014D\u00e9veloppement, Adaptation et Handicap, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Benveniste","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et immunologie clinique, h\u00f4pital de la Piti\u00e9 Salp\u00eatri\u00e8re, Sorbonne Universit\u00e9, APHP , Paris,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3388-0991","authenticated-orcid":false,"given":"Paul","family":"Decker","sequence":"additional","affiliation":[{"name":"D\u00e9partement de m\u00e9decine interne et immunologie clinique, CHRU Nancy , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]},{"name":"UMR 7365 CNRS-Universit\u00e9 de Lorraine IMoPA, Universit\u00e9 de Lorraine , Vand\u0153uvre-l\u00e8s-Nancy,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,1,29]]},"reference":[{"key":"2026020706065806500_keag032-B1","first-page":"782","article-title":"Clinical features and outcome in a Danish cohort of juvenile dermatomyositis patients","volume":"28","author":"Mathiesen","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"2026020706065806500_keag032-B2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fped.2018.00284","article-title":"The Vasculopathy of Juvenile Dermatomyositis","volume":"6","author":"Papadopoulou","year":"2018","journal-title":"Front Pediatr"},{"key":"2026020706065806500_keag032-B3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","article-title":"An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity","volume":"13","author":"Baechler","year":"2007","journal-title":"Mol Med"},{"key":"2026020706065806500_keag032-B4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/ar3531","article-title":"Type I interferon pathway in adult and juvenile dermatomyositis","volume":"13","author":"Baechler","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"2026020706065806500_keag032-B5","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/rheumatology\/kep302","article-title":"Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset","volume":"48","author":"Sanner","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B6","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1002\/art.24904","article-title":"Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index","volume":"60","author":"Rider","year":"2009","journal-title":"Arthritis Rheum"},{"key":"2026020706065806500_keag032-B7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41584-023-00967-9","article-title":"Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care","volume":"19","author":"Papadopoulou","year":"2023","journal-title":"Nat Rev Rheumatol"},{"key":"2026020706065806500_keag032-B8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2018.56","article-title":"Autoantibodies in myositis","volume":"14","author":"McHugh","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2026020706065806500_keag032-B9","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1038\/nrrheum.2011.139","article-title":"Clinical features, pathogenesis and treatment of juvenile and adult dermatomyositis","volume":"7","author":"Robinson","year":"2011","journal-title":"Nat Rev Rheumatol"},{"key":"2026020706065806500_keag032-B10","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1097\/RHU.0000000000001696","article-title":"Clinical Characteristics of Juvenile Idiopathic Inflammatory Myopathy and Comparison With Adult Patients: analysis From a Multicentric Cohort in Spain","volume":"28","author":"Loarce-Martos","year":"2022","journal-title":"J Clin Rheumatol"},{"key":"2026020706065806500_keag032-B11","first-page":"995","article-title":"Update on dermatomyositis in adults","volume":"18","author":"Schlecht","year":"2020","journal-title":"J Dtsch Dermatol Ges"},{"key":"2026020706065806500_keag032-B12","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1038\/s41584-024-01188-4","article-title":"An update on autoantibodies in the idiopathic inflammatory myopathies","volume":"21","author":"Allameen","year":"2025","journal-title":"Nat Rev Rheumatol"},{"key":"2026020706065806500_keag032-B13","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/ken441","article-title":"Distribution and severity of weakness among patients with polymyositis, dermatomyositis and juvenile dermatomyositis","volume":"48","author":"Harris-Love","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B14","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1002\/art.34659","article-title":"Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course","volume":"64","author":"Reed","year":"2012","journal-title":"Arthritis Rheum"},{"key":"2026020706065806500_keag032-B15","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/acr.22212","article-title":"Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies","volume":"66","author":"Huber","year":"2014","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020706065806500_keag032-B16","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3109\/03009742.2011.608376","article-title":"Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study","volume":"41","author":"Mathiesen","year":"2012","journal-title":"Scand J Rheumatol"},{"key":"2026020706065806500_keag032-B17","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2026020706065806500_keag032-B18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/acr.20071","article-title":"Protocols for the initial treatment of moderately severe juvenile dermatomyositis: results of a Children\u2019s Arthritis and Rheumatology Research Alliance Consensus Conference","volume":"62","author":"Huber","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026020706065806500_keag032-B19","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1136\/annrheumdis-2012-201483","article-title":"The PRINTO criteria for clinically inactive disease in juvenile dermatomyositis","volume":"72","author":"Lazarevic","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"2026020706065806500_keag032-B20","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1002\/art.21291","article-title":"International consensus guidelines for trials of therapies in the idiopathic inflammatory myopathies","volume":"52","author":"Oddis","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026020706065806500_keag032-B21","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: an Official ATS\/ERS\/JRS\/ALAT Clinical Practice Guideline","volume":"205","author":"Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"key":"2026020706065806500_keag032-B22","first-page":"470","article-title":"Vasculopathy-related clinical and pathological features are associated with severe juvenile dermatomyositis","volume":"55","author":"Gitiaux","year":"2016","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B23","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/rheumatology\/kex516","article-title":"Muscle ischaemia associated with NXP2 autoantibodies: a severe subtype of juvenile dermatomyositis","volume":"57","author":"Aouizerate","year":"2018","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.jaut.2017.06.007","article-title":"Autoantibodies in juvenile-onset myositis: their diagnostic value and associated clinical phenotype in a large UK cohort","volume":"84","author":"Tansley","year":"2017","journal-title":"J Autoimmun"},{"key":"2026020706065806500_keag032-B25","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1002\/art.42861","article-title":"2023 American College of Rheumatology (ACR)\/American College of Chest Physicians (CHEST) Guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases","volume":"76","author":"Johnson","year":"2024","journal-title":"Arthritis Rheumatol"},{"key":"2026020706065806500_keag032-B26","doi-asserted-by":"crossref","first-page":"R138","DOI":"10.1186\/ar4600","article-title":"Anti-MDA5 autoantibodies in juvenile dermatomyositis identify a distinct clinical phenotype: a prospective cohort study","volume":"16","author":"Tansley","year":"2014","journal-title":"Arthritis Res Ther"},{"key":"2026020706065806500_keag032-B27","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2026020706065806500_keag032-B28","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/rheumatology\/keaa739","article-title":"Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis","volume":"60","author":"Fornaro","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B29","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jdermsci.2016.09.013","article-title":"Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis","volume":"84","author":"Fujimoto","year":"2016","journal-title":"J Dermatol Sci"},{"key":"2026020706065806500_keag032-B30","doi-asserted-by":"crossref","first-page":"e1768","DOI":"10.1212\/WNL.0000000000008443","article-title":"More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies","volume":"93","author":"Pinal-Fernandez","year":"2019","journal-title":"Neurology"},{"key":"2026020706065806500_keag032-B31","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/annrheumdis-2018-215004","article-title":"Anti-Ro52 autoantibodies are associated with interstitial lung disease and more severe disease in patients with juvenile myositis","volume":"78","author":"Sabbagh","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026020706065806500_keag032-B32","doi-asserted-by":"crossref","first-page":"106134","DOI":"10.1016\/j.rmed.2020.106134","article-title":"Anti-Ro52 antibody is an independent risk factor for interstitial lung disease in dermatomyositis","volume":"172","author":"Xing","year":"2020","journal-title":"Respir Med"},{"key":"2026020706065806500_keag032-B33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s12969-022-00754-y","article-title":"Juvenile Dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective","volume":"20","author":"Boros","year":"2022","journal-title":"Pediatr Rheumatol Online J"},{"key":"2026020706065806500_keag032-B34","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1093\/rheumatology\/keaa371","article-title":"Corticosteroid discontinuation, complete clinical response and remission in juvenile dermatomyositis","volume":"60","author":"Kishi","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B35","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/RHU.0000000000002092","article-title":"Factors associated with complete clinical response and remission in a cohort of romanian children with juvenile dermatomyositis","volume":"30","author":"Ioan","year":"2024","journal-title":"J Clin Rheumatol"},{"key":"2026020706065806500_keag032-B36","doi-asserted-by":"crossref","first-page":"e11751","DOI":"10.1002\/acr2.11751","article-title":"Achieving medication-free remission in patients with juvenile dermatomyositis","volume":"7","author":"Maccora","year":"2025","journal-title":"ACR Open Rheumatol"},{"key":"2026020706065806500_keag032-B37","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.reuma.2016.07.010","article-title":"Multicenter registry on inflammatory myositis from the rheumatology society in Madrid, Spain: descriptive analysis","volume":"13","author":"Nu\u00f1o","year":"2017","journal-title":"Reumatol Clin"},{"key":"2026020706065806500_keag032-B38","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1093\/rheumatology\/kel099","article-title":"The Juvenile Dermatomyositis National Registry and Repository (UK and Ireland)\u2014clinical characteristics of children recruited within the first 5 yr","volume":"45","author":"McCann","year":"2006","journal-title":"Rheumatology (Oxford)"},{"key":"2026020706065806500_keag032-B39","doi-asserted-by":"crossref","first-page":"16444","DOI":"10.1038\/s41598-023-43880-7","article-title":"Incidence and prevalence, and medication use among adults living with dermatomyositis: an Alberta, Canada population-based cohort study","volume":"13","author":"Osman","year":"2023","journal-title":"Sci Rep"},{"key":"2026020706065806500_keag032-B40","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.nmd.2022.05.011","article-title":"256th ENMC international workshop: myositis specific and associated autoantibodies (MSA-ab): amsterdam, The Netherlands, 8-10 October 2021","volume":"32","author":"Damoiseaux","year":"2022","journal-title":"Neuromuscul Disord"},{"key":"2026020706065806500_keag032-B41","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1007\/s00296-024-05551-2","article-title":"Baricitinib for anti-melanoma differentiation-associated protein 5 antibody-positive dermatomyositis-associated interstitial lung disease: a case series and literature review on Janus kinase inhibitors for the disease","volume":"44","author":"Harada","year":"2024","journal-title":"Rheumatol Int"},{"key":"2026020706065806500_keag032-B42","doi-asserted-by":"crossref","first-page":"e002795","DOI":"10.1136\/rmdopen-2022-002795","article-title":"Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis","volume":"9","author":"Ida","year":"2023","journal-title":"RMD Open"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keag032\/66564675\/keag032.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag032\/66564675\/keag032.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/65\/2\/keag032\/66564675\/keag032.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T11:07:07Z","timestamp":1770462427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/doi\/10.1093\/rheumatology\/keag032\/8440152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,29]]},"references-count":42,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2,4]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keag032","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2026,1,29]]},"article-number":"keag032"}}